NANS inhibitors are chemical compounds that target and inhibit the activity of the N-acetylneuraminic acid synthase (NANS) enzyme. NANS is a crucial enzyme involved in the biosynthetic pathway of sialic acids, particularly N-acetylneuraminic acid (Neu5Ac), which is a key component of glycoproteins and glycolipids in many organisms, including humans. Sialic acids play important structural and regulatory roles in various biological processes, especially in cellular communication, molecular recognition, and the maintenance of cell membrane integrity. By interfering with the function of NANS, inhibitors of this enzyme can disrupt the production of sialic acids, thereby influencing the expression and function of sialylated molecules in biological systems. This can result in altered molecular interactions and signaling pathways due to the diminished presence of sialic acids in glycan structures.
Structurally, NANS inhibitors are designed to mimic the natural substrates or transition states of the NANS enzyme, binding to its active site with high affinity and blocking the enzyme's catalytic function. Some of these inhibitors are small organic molecules, often with functional groups that interact with key residues in the NANS active site, forming stable complexes that prevent the enzyme from catalyzing the condensation reaction between N-acetylmannosamine (ManNAc) and phosphoenolpyruvate (PEP), the precursors to Neu5Ac. Due to their targeted nature, the development of NANS inhibitors requires a deep understanding of the enzyme's structure, mechanism, and substrate specificity. Advances in structural biology techniques, such as X-ray crystallography and molecular dynamics simulations, have been instrumental in identifying and refining potent NANS inhibitors by revealing how these compounds interact at the molecular level with the enzyme. This class of inhibitors has significant importance in understanding the fundamental biochemical pathways involving sialic acid biosynthesis and its broader implications for cellular and molecular biology.
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
UDP-α-D-Galactose disodium salt | 137868-52-1 | sc-286849 sc-286849A | 10 mg 50 mg | $102.00 $194.00 | 1 | |
Changes in UDP levels might modulate the enzymatic activity of NANS, as UDP-GlcNAc is a precursor in sialic acid synthesis. | ||||||
Acetic acid | 64-19-7 | sc-214462 sc-214462A | 500 ml 2.5 L | $62.00 $104.00 | 5 | |
Altered acetate levels can disrupt the availability of Acetyl-CoA, an important cofactor, indirectly impacting NANS function. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $135.00 $246.00 $619.00 $799.00 $1796.00 | 6 | |
By affecting glycosylation, this compound can indirectly impact the availability of substrates for NANS. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $65.00 $210.00 | 26 | |
This glucose analog can disrupt various cellular pathways, potentially impacting sialic acid synthesis and indirectly NANS function. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
This compound inhibits N-acetylglucosamine transferase, impacting glycosylation and potentially the activity of NANS. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $180.00 $620.00 | 10 | |
By inhibiting glucosidases, it can indirectly affect the availability of substrates or the overall pathway in which NANS operates. |